# Bonk, Inc.

**BNKK**

Nasdaq; chemicals; SIC 2844, Perfumes, Cosmetics & Other Toilet Preparations; CIK 0001760903

# D/E

**on the D/E boundary of 331 graded peers in the pooled indus...**

rank 252 of 331; percentile 80.0; sampling error 2.7 points; lower is stronger

A B C D E

**D/E, the sloth**




| Scoreboard | |
|---|---|
| **Profitability** | D<br>percentile 63.8 |
| **Solvency** | E<br>percentile 91.2 |
| **Growth and financing** | B<br>percentile 33.8 |
| **Reliability** | 0.83 AUC<br>filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025 |
| **Peer failure rate** | 1.07% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $12.5M to $120M assets<br>total assets $41.0M |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | dilution, late filer<br>not computable: short runway, distress, fortress balance sheet |
| **Inputs computable** | 7 of 14 |
| **Graded from** | filings received through Mar 31, 2026<br>212 days before the rescan; latest periodic filing 10-Q received Aug 14, 2026 |
| **Last close** | $1.18<br>2026-10-28; market equity $9.4M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 31, 2026*

Inc. (NASDAQ: BNKK) was formerly known as Safety Shot, Inc., and prior to that, Jupiter Wellness, Inc. August 2023 Jupiter Wellness, Inc. acquired certain assets of GBB Drink Lab Inc which included the blood alcohol reduction drink Sure Shot (the "Sure Shot Dietary Supplement"), an over-the-counter drink that can lower blood alcohol content to allow recovery from the effects of alcohol by supporting its metabolism, relying on 28 active ingredients, all falling under the FDA's Generally Regarded As Safe (GRAS) category.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 63.8** | | | | | | |
| Gross profitability | 3.0% | 21.3% | | 91.1 | 360 | 2025-12-31 |
| Return on invested capital | not computable | 9.3% | | | | |
| *one or more required annual facts are missing* | | | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | |
|---|---|---|---|---|---|
| Accruals ratio | (177.6%) | (4.2%) | 0.5 | 399 | 2025-12-31 |
| Gross margin stability, five years | 148.1 pts | 2.2 pts | 99.7 | 301 | 2025-12-31 |
| **Solvency, sleeve percentile 91.2** | | | | | |
| Twelve-month failure probability | not computable | 0.04% | | | |
| *latest liabilities, cash plus short-term investments, book equity, and shares are required* | | | | | |
| Altman Z double-prime | not computable | 3.41 | | | |
| *one or more required annual facts are missing* | | | | | |
| Net debt to EBITDA | not computable | 1.88x | | | |
| *one or more required annual facts are missing* | | | | | |
| Interest coverage | not computable | 4.16x | | | |
| *one or more required annual facts are missing* | | | | | |
| Current ratio | 1.01x | 2.20x | 91.2 | 422 | 2025-12-31 |
| **Growth and financing, sleeve percentile 33.8** | | | | | |
| Revenue growth, three-year compound | 159.9% | 1.2% | 0.6 | 350 | 2025-12-31 |
| Free cash flow growth, three-year compound | not computable | 12.5% | | | |
| *four consecutive annual FCF observations are required; found 3* | | | | | |
| Reinvestment rate | not computable | 21.8% | | | |
| *one or more required annual facts are missing* | | | | | |
| Asset growth, three years | 67.7% | 2.9% | 2.7 | 367 | 2025-12-31 |
| Net share issuance, one year | 269.0% | 0.0% | 98.1 | 318 | 2026-03-25 |


## Warnings

*2 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Dilution | split-adjusted year-over-year share growth is 269.0% |
| Late filer | found 1 NT 10-K/Q filings in the last eight quarters |

## Among 331 peers

*chemicals; letters are fifths of this list*




*Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.*

| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 247 | Silgan Holdings Inc. (SLGN) | 78.7 | D/E | |
| 248 | Westlake Corp. (WLK) | 78.8 | D/E | |
| 249 | Regal Rexnord Corp. (RRX) | 79.1 | D/E | |
| 250 | Mercer International Inc. (MERC) | 79.5 | D/E | |
| 251 | NN Inc. (NNBR) | 79.9 | D/E | |
| 252 | Bonk, Inc. (BNKK) | 80.0 | D/E | dilution, late filer |
| 253 | Redwire Corp. (RDW) | 80.3 | D/E | dilution, fortress balance sheet |
| 254 | American Superconductor Corp. (AMSC) | 80.7 | D/E | |
| 255 | American Vanguard Corp. (AVD) | 80.9 | D/E | late filer |
| 256 | Crane NXT, Co. (CXT) | 81.1 | D/E | |
| 257 | Coty Inc. (COTY) | 81.2 | D/E | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

## What the price implies

*at the 2026-10-28 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | (86.9%) | 13.8% | 0 |
| Distance from 52-week high | (85.3%) | (25.2%) | 2 |
| EBIT to enterprise value | not computable | 3.8% | |
| Free cash flow yield | (187.8%) | 3.3% | 0 |
| Book value to price | 2.84 | 0.38 | 98 |
| Sales to price | 0.22 | 0.55 | 15 |
| Composite equity issuance, five years | 321.4% | (9.9%) | 98 |
| Relative strength against the sector, log excess return | (2.20) | (0.02) | 0 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | pass |
| No new shares issued | fail |
| Gross margin improved | pass |
| Asset turnover improved | pass |
| **Cash, filings, liquidity** | |
| Cash and equivalents | n/a |
| Operating cash flow, four quarters | n/a |
| Months of runway | not finite |
| Days since last periodic filing | 76 (10-Q received Aug 14, 2026) |
| Median daily dollar volume, 63 sessions | $114,340 |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | gross profit | us-gaap:GrossProfit | $1.2M | 2025-12-31 | 2026-03-31 | 10-K | 26-014015 |
| 2 | assets | us-gaap:Assets | $41.0M | 2025-12-31 | 2026-03-31 | 10-K | 26-014015 |
| 3 | net income | us-gaap:NetIncomeLoss | -$68.2M | 2025-12-31 | 2026-03-31 | 10-K | 26-014015 |
| 4 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivitiesC... | -$25.3M | 2025-12-31 | 2026-03-31 | 10-K | 26-014015 |
| 5 | assets | us-gaap:Assets | $7.3M | 2024-12-31 | 2026-03-31 | 10-K | 26-014015 |
| 6 | revenue | us-gaap:Revenues | $2.1M | 2025-12-31 | 2026-03-31 | 10-K | 26-014015 |
| 7 | gross profit | us-gaap:GrossProfit | -$2.4M | 2024-12-31 | 2026-03-31 | 10-K | 26-014015 |
| 8 | revenue | us-gaap:Revenues | $701,967 | 2024-12-31 | 2026-03-31 | 10-K | 26-014015 |
| 9 | gross profit | us-gaap:GrossProfit | -$74,457 | 2023-12-31 | 2025-03-28 | 10-K | 25-001259 |
| 10 | revenue | us-gaap:Revenues | $202,670 | 2023-12-31 | 2025-03-28 | 10-K | 25-001259 |
| 11 | gross profit | us-gaap:GrossProfit | -$204,542 | 2022-12-31 | 2024-04-01 | 10-K | 24-012476 |
| 12 | revenue | us-gaap:Revenues | $120,627 | 2022-12-31 | 2024-04-01 | 10-K | 24-012476 |
| 13 | gross profit | us-gaap:GrossProfit | $535,485 | 2021-12-31 | 2023-04-03 | 10-K | 23-010480 |
| 14 | revenue | us-gaap:Revenues | $2.9M | 2021-12-31 | 2023-04-03 | 10-K | 23-010480 |
| 15 | current assets | us-gaap:AssetsCurrent | $6.0M | 2025-12-31 | 2026-03-31 | 10-K | 26-014015 |
| 16 | current liabilities | us-gaap:LiabilitiesCurrent | $6.0M | 2025-12-31 | 2026-03-31 | 10-K | 26-014015 |
| 17 | assets | us-gaap:Assets | $12.7M | 2023-12-31 | 2025-03-28 | 10-K | 25-001259 |
| 18 | assets | us-gaap:Assets | $8.7M | 2022-12-31 | 2024-04-01 | 10-K | 24-012476 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| 19 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 7,851,315 | 2026-03-25 | 2026-03-31 | 10-K | 26-014015 |
| 20 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 74,451,604 | 2025-03-25 | 2025-03-28 | 10-K | 25-001259 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.